GoldenGolden
Codagenix

Codagenix

A biotechnology company developing live attenuated vaccines. It was founded in 2012 and is located in New York.

Company

Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus.

The company's product pipeline includes vaccines for influenza, respiratory syncytial virus (RSV), dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.

COVID-19

In February 2020, the company teamed up with the Serum Institute of India to co-develop a live-attenuated vaccine for COVID-19. The company uses viral deoptimization technology in order to create multiple vaccine candidates for a virus.

Timeline

January 13, 2020
Codagenix raises a $20,000,000 series B round from Adjuvant Capital, Euclidean Capital and Topspin Partners.
2020
Codagenix was founded by Charlie Petty, Eckard Wimmer, Glenn Rockman, J. Robert Coleman and Steffen Mueller.
October 12, 2017
Codagenix raises a $3,000,000 venture round from Topspin Partners.
June 12, 2015
Codagenix raises a $2,000,000 series A round from Topspin Partners.
June 28, 2014
Codagenix raises a $1,200,000 grant.
July 1, 2012
Codagenix raises a $600,000 grant.

Funding rounds

People

Name
Role
LinkedIn

Eckard Wimmer

Co-Founder, Senior Scientific Officer

J. Robert Coleman

Co-Founder & COO

Rishab Kaul

Employee

Steffen Mueller

Co-Founder, President, and Chief Scientific Officer

Further reading

Title
Author
Link
Type
Date

Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19

Web

February 13, 2020

Xconomy: With $2M, Codagenix Becomes Accelerate LI's First VC-Backed Grad

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Technavio
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- The dengue vaccine market is expected to grow by USD 132.90 million during 2021-2025, according to Technavio. The report offers a detailed...
BioSpace
May 4, 2021
BioSpace
Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice President, Oncology.
April 14, 2021
BioSpace
Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls - read this article along with other careers information, tips and advice on BioSpace
Christine Hall
December 15, 2020
Crunchbase News
Hundreds of startups focused on vaccines, testing kits and other COVID-19 products are riding the big pharma momentum, eager to get their own products to market in the next year.
February 15, 2020
The Economic Times
Some vaccine candidates for China virus are already at trial stage. But path to pharmacy is strewn with hurdles.
Jonathan Shieber
January 14, 2020
TechCrunch
Coadagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever has raised $20 million in a new round of financing. The company's new investment round was led by Adjuvant Capital with additional participation from Euclidean Capital and Topspin Partners . Codagenix will use the funds [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.